Parallel Bio Appoints Jason Lew as Chief AI Officer
The biotech startup expands its AI-led drug screening platform to help reduce clinical trial failure rates.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Should pharmaceutical companies prioritize human-based biological testing over traditional animal models for new drug development?
Parallel Bio, a biotechnology firm established in 2021, has appointed Jason Lew as its Chief AI Officer. The company operates a platform that utilizes human immune organoids to predict drug efficacy, aiming to address the high failure rate of experimental medicines in human trials.
Why it matters
The development of reliable human-in-the-loop biological systems is critical for an industry where more than 95% of drugs that clear animal testing fail in subsequent human trials. By integrating large language models with automated organoid testing, the company seeks to improve the translational success of new therapies.
The company maintains a platform currently utilized by 5 Fortune 500 companies that runs automated experiments on immune organoids. These systems serve as a proxy for human response, contrasting with traditional animal models that frequently fail to predict clinical outcomes.
The players
Parallel Bio
A biotechnology firm with offices in San Francisco and Vienna that uses human immune organoids and automated testing to predict drug outcomes.
Jason Lew
A veteran of Apple and Instacart who began building large language model products in 2020 and now leads the AI strategy at Parallel Bio.
The details
Parallel Bio maintains a biobank of human immune organoids—three-dimensional tissue cultures that mimic the structure and function of the human immune system. The company uses robotics to conduct large-scale experiments on these samples to generate data, which is then accessible to partners through an API and an MCP (Model Context Protocol) server. This infrastructure allows external researchers to interface with the organoid data using computational models to simulate drug interactions.
Timeline
2020: Jason Lew began developing products using large language models.
2021: Parallel Bio was founded.
2026: Parallel Bio was named a World Economic Forum Technology Pioneer.
October 27, 2026: Jason Lew was appointed Chief AI Officer.
The Tech Race
Parallel Bio is competing against traditional pre-clinical models that rely on animal testing, which often fail to mirror human physiological responses. By positioning itself as a 2026 World Economic Forum Technology Pioneer, the firm aims to scale its automated organoid-as-a-service model against established pharmaceutical R&D benchmarks.
The firm’s platform is currently restricted to its 5 existing Fortune 500 partners who access the system via API and MCP server. Broader utility for the wider research community depends on future scaling of the organoid biobank and the expansion of the AI-driven simulation interface.
The takeaway
The appointment of a dedicated AI lead signals that the firm intends to increase the computational throughput of its existing organoid testing pipeline. Observers should track whether the company expands its API access beyond the current group of five Fortune 500 partners in the coming year.
Further reading
Explore more trends in Biotech to understand how automated organoid platforms are shaping the next generation of drug discovery.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should pharmaceutical companies prioritize human-based biological testing over traditional animal models for new drug development?
